Login to Your Account

Sutro Self: $500M Celgene Tie to 'Kick Tires' in ADC, More

By Randy Osborne
Staff Writer

Wednesday, December 19, 2012
The potential $500 million deal signed by Sutro Biopharma Inc. with Celgene Corp. includes two undisclosed targets against which antibody conjugates and bispecific antibodies will be deployed, plus the manufacturing of a Celgene-owned antibody, as the latter company explores Sutro's platform in multiple areas.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription